Rose Robert A
Dalhousie University, Department of Physiology and Biophysics, Sir Charles Tupper Medical Building, Laboratory 3F, 5850 College Street, Halifax, Nova Scotia B3H1X5, Canada.
Curr Opin Investig Drugs. 2010 Mar;11(3):349-56.
In development by Nile Therapeutics Inc, under license from the Mayo Foundation, CD-NP is a chimeric natriuretic peptide in which the 15-amino acid C-terminal tail of Dendroaspis natriuretic peptide is fused to the 22-amino acid human C-type natriuretic peptide. The rationale for its design was to create a peptide with the beneficial cardiovascular and renal effects of native natriuretic peptides, but without a clinically significant hypotensive response. CD-NP is able to bind to all three natriuretic peptide receptors (NPR-A, NPR-B and NPR-C) and, therefore, is unique in being able to increase cyclic guanosine monophosphate production downstream of both NPR-A and NPR-B. Animal studies and human trials demonstrated that CD-NP is safe and improves cardiovascular and renal function without inducing significant levels of hypotension. Preliminary data also suggest improved renal function in human heart failure patients. Ongoing clinical trials are needed to further validate CD-NP as an effective treatment option for heart failure.
CD-NP由尼罗治疗公司（Nile Therapeutics Inc）根据梅奥基金会（Mayo Foundation）的许可进行研发，是一种嵌合型利钠肽，其中树眼镜蛇利钠肽的15个氨基酸的C末端尾巴与22个氨基酸的人C型利钠肽融合。其设计原理是创造一种具有天然利钠肽有益的心血管和肾脏作用，但无临床显著降压反应的肽。CD-NP能够与所有三种利钠肽受体（NPR-A、NPR-B和NPR-C）结合，因此，其独特之处在于能够增加NPR-A和NPR-B下游的环磷酸鸟苷生成。动物研究和人体试验表明，CD-NP是安全的，可改善心血管和肾脏功能，而不会引起显著程度的低血压。初步数据还表明，它可改善人类心力衰竭患者的肾功能。需要进行正在进行的临床试验，以进一步验证CD-NP作为心力衰竭有效治疗选择的有效性。
